Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Telomerase RNA component (TERC), also known as hTR or hTERC, is a non-coding RNA molecule that serves as an essential structural and functional component of the human telomerase ribonucleoprotein complex. It contains a critical template sequence (3'-CAAUCC-5') that is utilized by the catalytic subunit, telomerase reverse transcriptase (TERT), to synthesize and append telomeric DNA repeats (TTAGGG) to the 3' ends of linear chromosomes. This process counteracts the progressive shortening of telomeres that occurs during DNA replication, thereby preventing cellular senescence and apoptosis. While telomerase activity is tightly repressed in most normal somatic cells, it is highly upregulated in approximately 85-90% of human cancers and neoplastic progenitor cells, conferring replicative immortality. Consequently, TERC represents a compelling therapeutic target in oncology and hematologic malignancies. Drugs like imetelstat, a first-in-class lipid-conjugated oligonucleotide, directly bind to the template region of TERC, competitively inhibiting telomerase activity and driving malignant cells into replicative crisis and cell death. Conversely, loss-of-function mutations in TERC are associated with bone marrow failure syndromes and degenerative diseases, such as dyskeratosis congenita, aplastic anemia, and idiopathic pulmonary fibrosis.
Imetelstat is a lipid-conjugated oligonucleotide that competitively binds to the template region of the telomerase RNA component (TERC/hTR). This binding prevents the hybridization of telomeric DNA and inhibits the enzymatic activity of the telomerase complex, leading to progressive telomere shortening, cellular senescence, and apoptosis in telomerase-dependent cells.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Telomerase RNA component (TERC) (TERC).